Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic diseases and inflammation for patients who have limited or no approved treatment options. Co.'s primary product is Andexxa, an antidote for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Bevyxxa is an anticoagulant approved for hospital and extended duration prophylaxis of venous thromboembolism in adult patients. Cerdulatinib is Co.'s investigational oral, dual spleen tyrosine kinase and janus kinase inhibitor. We show 30 historical shares outstanding datapoints in our PTLA shares outstanding history coverage, used to compute PTLA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PTLA market cap history over the course of time is important for investors
interested in comparing PTLA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PTLA versus a peer is one thing; comparing
PTLA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PTLA can fluctuate over the course of history.
With this page we aim to empower investors researching PTLA by allowing them to research the PTLA market cap history. |
Free PTLA Email Alerts:
Video: The Importance of Market Cap
